| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.829 | 0.003 | 0.829 | 5 Hydroxytryptamine 1A agonist | 0.624 0.004 DBMET03723 0.665 0.004 DBMET03725 0.624 0.004 DBMET03727 0.545 0.004 DBMET03728 0.604 0.004 DBMET03729 0.512 0.004 DBMET03724 0.2 0.009 DBMET03726 | ||
| 0.649 | 0.01 | 0.666 | Vasodilator, peripheral | 0.661 0.009 DBMET03723 0.596 0.017 DBMET03725 0.666 0.009 DBMET03727 0.653 0.01 DBMET03728 0.629 0.013 DBMET03729 0.589 0.017 DBMET03724 0.557 0.02 DBMET03726 | DBMET03727 | |
| 0.631 | 0.004 | 0.631 | 5 Hydroxytryptamine 1 agonist | 0.38 0.005 DBMET03723 0.449 0.005 DBMET03725 0.394 0.005 DBMET03727 0.334 0.005 DBMET03728 0.45 0.005 DBMET03729 0.293 0.007 DBMET03724 0.14 0.015 DBMET03726 | ||
| 0.637 | 0.031 | 0.664 | Caspase 9 stimulant | 0.513 0.055 DBMET03723 0.519 0.053 DBMET03725 0.53 0.05 DBMET03727 0.54 0.047 DBMET03728 0.664 0.028 DBMET03729 0.415 0.102 DBMET03724 0.536 0.048 DBMET03726 | DBMET03729 | |
| 0.589 | 0.005 | 0.589 | Alpha adrenoreceptor antagonist | 0.341 0.013 DBMET03723 0.327 0.014 DBMET03725 0.418 0.009 DBMET03727 0.234 0.022 DBMET03728 0.279 0.017 DBMET03729 0.191 0.029 DBMET03724 0.114 0.05 DBMET03726 | ||
| 0.572 | 0.004 | 0.572 | Alpha 1 adrenoreceptor antagonist | 0.321 0.01 DBMET03723 0.299 0.011 DBMET03725 0.267 0.013 DBMET03727 0.242 0.016 DBMET03728 0.235 0.016 DBMET03729 0.179 0.024 DBMET03724 0.084 0.051 DBMET03726 | ||
| 0.552 | 0.004 | 0.552 | 5 Hydroxytryptamine 1A antagonist | 0.247 0.011 DBMET03723 0.235 0.012 DBMET03725 0.216 0.013 DBMET03727 0.216 0.013 DBMET03728 0.208 0.014 DBMET03729 0.108 0.029 DBMET03724 0.064 0.05 DBMET03726 | ||
| 0.547 | 0.003 | 0.547 | Alpha 1d adrenoreceptor antagonist | 0.301 0.005 DBMET03723 0.301 0.005 DBMET03725 0.249 0.007 DBMET03727 0.26 0.006 DBMET03728 0.19 0.01 DBMET03729 0.164 0.013 DBMET03724 0.07 0.035 DBMET03726 | ||
| 0.529 | 0.004 | 0.529 | Alpha 1a adrenoreceptor antagonist | 0.284 0.01 DBMET03723 0.253 0.012 DBMET03725 0.231 0.013 DBMET03727 0.192 0.017 DBMET03728 0.21 0.015 DBMET03729 0.145 0.024 DBMET03724 0.074 0.048 DBMET03726 | ||
| 0.527 | 0.005 | 0.527 | Antiadrenergic | 0.33 0.012 DBMET03723 0.402 0.008 DBMET03725 0.382 0.009 DBMET03727 0.255 0.017 DBMET03728 0.375 0.009 DBMET03729 0.277 0.015 DBMET03724 0.216 0.021 DBMET03726 | ||
| 0.525 | 0.005 | 0.525 | Adrenaline antagonist | 0.328 0.011 DBMET03723 0.4 0.008 DBMET03725 0.38 0.009 DBMET03727 0.245 0.017 DBMET03728 0.374 0.009 DBMET03729 0.274 0.015 DBMET03724 0.214 0.021 DBMET03726 | ||
| 0.522 | 0.004 | 0.522 | Alpha 1b adrenoreceptor antagonist | 0.297 0.008 DBMET03723 0.297 0.008 DBMET03725 0.255 0.01 DBMET03727 0.215 0.013 DBMET03728 0.21 0.014 DBMET03729 0.17 0.018 DBMET03724 0.086 0.042 DBMET03726 | ||
| 0.517 | 0.004 | 0.517 | 5 Hydroxytryptamine 1 antagonist | 0.212 0.016 DBMET03723 0.216 0.015 DBMET03725 0.2 0.017 DBMET03727 0.171 0.02 DBMET03728 0.209 0.016 DBMET03729 0.095 0.039 DBMET03724 0.066 0.058 DBMET03726 | ||
| 0.515 | 0.007 | 0.515 | 5 Hydroxytryptamine antagonist | 0.165 0.044 DBMET03723 0.197 0.035 DBMET03725 0.179 0.039 DBMET03727 0.159 0.046 DBMET03728 0.263 0.023 DBMET03729 | ||
| 0.504 | 0.009 | 0.534 | Interleukin agonist | 0.491 0.009 DBMET03723 0.427 0.015 DBMET03725 0.534 0.007 DBMET03727 0.374 0.023 DBMET03728 0.431 0.015 DBMET03729 0.396 0.019 DBMET03724 0.353 0.028 DBMET03726 | DBMET03727 | |
| 0.499 | 0.003 | 0.499 | Alpha 1 adrenoreceptor agonist | 0.16 0.009 DBMET03723 0.24 0.005 DBMET03725 0.221 0.005 DBMET03727 0.106 0.015 DBMET03728 0.359 0.004 DBMET03729 0.076 0.025 DBMET03724 0.149 0.009 DBMET03726 | ||
| 0.472 | 0.008 | 0.505 | Calcium channel activator | 0.438 0.014 DBMET03723 0.433 0.015 DBMET03725 0.453 0.01 DBMET03727 0.356 0.046 DBMET03728 0.505 0.005 DBMET03729 0.403 0.024 DBMET03724 0.472 0.008 DBMET03726 | DBMET03729 | |
| 0.495 | 0.036 | 0.502 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.368 0.131 DBMET03723 0.383 0.116 DBMET03725 0.382 0.118 DBMET03727 0.395 0.105 DBMET03728 0.502 0.033 DBMET03729 0.294 0.221 DBMET03724 0.391 0.109 DBMET03726 | DBMET03729 | |
| 0.435 | 0.005 | 0.59 | 5 Hydroxytryptamine agonist | 0.169 0.018 DBMET03723 0.23 0.012 DBMET03725 0.182 0.016 DBMET03727 0.135 0.024 DBMET03728 0.59 0.004 DBMET03729 0.111 0.03 DBMET03724 0.276 0.009 DBMET03726 | DBMET03729 | |
| 0.407 | 0.009 | 0.407 | 5 Hydroxytryptamine 2 antagonist | 0.173 0.037 DBMET03723 0.193 0.032 DBMET03725 0.182 0.035 DBMET03727 0.143 0.047 DBMET03728 0.236 0.023 DBMET03729 0.098 0.073 DBMET03724 0.1 0.071 DBMET03726 | ||
| 0.414 | 0.02 | 0.43 | Psychostimulant | 0.313 0.039 DBMET03723 0.341 0.033 DBMET03725 0.43 0.018 DBMET03727 0.414 0.02 DBMET03728 0.327 0.036 DBMET03729 0.239 0.063 DBMET03724 0.253 0.058 DBMET03726 | DBMET03727 | |
| 0.395 | 0.003 | 0.395 | Dopamine D5 antagonist | 0.226 0.005 DBMET03723 0.316 0.004 DBMET03725 0.236 0.004 DBMET03727 0.225 0.005 DBMET03728 0.069 0.015 DBMET03729 0.195 0.005 DBMET03724 0.046 0.028 DBMET03726 | ||
| 0.388 | 0.005 | 0.388 | Dopamine D4 antagonist | 0.096 0.027 DBMET03723 0.167 0.016 DBMET03725 0.154 0.017 DBMET03727 0.062 0.041 DBMET03728 0.106 0.024 DBMET03729 | ||
| 0.388 | 0.008 | 0.388 | Dopamine antagonist | 0.139 0.028 DBMET03723 0.192 0.019 DBMET03725 0.183 0.021 DBMET03727 0.099 0.039 DBMET03728 0.112 0.034 DBMET03729 0.074 0.051 DBMET03724 | ||
| 0.383 | 0.008 | 0.383 | 5 Hydroxytryptamine 2A antagonist | 0.146 0.029 DBMET03723 0.167 0.024 DBMET03725 0.137 0.032 DBMET03727 0.127 0.035 DBMET03728 0.19 0.021 DBMET03729 0.086 0.055 DBMET03724 0.077 0.061 DBMET03726 | ||
| 0.375 | 0.008 | 0.375 | Dopamine D2 antagonist | 0.132 0.025 DBMET03723 0.184 0.018 DBMET03725 0.116 0.028 DBMET03727 0.096 0.034 DBMET03728 0.096 0.034 DBMET03729 0.066 0.046 DBMET03724 | ||
| 0.368 | 0.004 | 0.439 | Alpha adrenoreceptor agonist | 0.145 0.017 DBMET03723 0.191 0.009 DBMET03725 0.188 0.01 DBMET03727 0.091 0.032 DBMET03728 0.439 0.004 DBMET03729 0.067 0.049 DBMET03724 0.243 0.006 DBMET03726 | DBMET03729 | |
| 0.386 | 0.024 | 0.386 | Anticonvulsant | 0.188 0.092 DBMET03723 0.214 0.074 DBMET03725 0.174 0.104 DBMET03727 0.294 0.042 DBMET03728 0.175 0.103 DBMET03729 | ||
| 0.356 | 0.012 | 0.356 | Ca(v)3.3 blocker | 0.237 0.121 DBMET03723 0.308 0.036 DBMET03725 0.258 0.089 DBMET03727 0.292 0.05 DBMET03728 0.208 0.175 DBMET03724 | ||
| 0.292 | 0.005 | 0.407 | Glutamate (mGluR) agonist | 0.407 0.004 DBMET03723 0.22 0.008 DBMET03725 0.213 0.008 DBMET03727 0.118 0.019 DBMET03728 0.389 0.004 DBMET03724 | DBMET03723 | |
| 0.3 | 0.046 | 0.408 | Potassium channel blocker | 0.408 0.021 DBMET03729 | DBMET03729 | |
| 0.25 | 0.008 | 0.25 | Dopamine D3 antagonist | 0.063 0.042 DBMET03723 0.106 0.023 DBMET03725 0.12 0.02 DBMET03727 0.054 0.051 DBMET03728 0.072 0.037 DBMET03729 | ||
| 0.248 | 0.01 | 0.248 | Alpha 2c adrenoreceptor antagonist | 0.14 0.037 DBMET03723 0.166 0.026 DBMET03725 0.198 0.018 DBMET03727 0.221 0.014 DBMET03729 0.105 0.062 DBMET03724 0.146 0.034 DBMET03726 | ||
| 0.244 | 0.015 | 0.294 | Alpha 2b adrenoreceptor antagonist | 0.116 0.062 DBMET03723 0.144 0.041 DBMET03725 0.171 0.031 DBMET03727 0.294 0.009 DBMET03729 0.185 0.027 DBMET03726 | DBMET03729 | |
| 0.24 | 0.012 | 0.256 | Alpha 2 adrenoreceptor antagonist | 0.101 0.047 DBMET03723 0.143 0.029 DBMET03725 0.197 0.018 DBMET03727 0.256 0.011 DBMET03729 0.154 0.026 DBMET03726 | DBMET03729 | |
| 0.245 | 0.019 | 0.245 | 5 Hydroxytryptamine 2B antagonist | 0.093 0.092 DBMET03723 0.127 0.054 DBMET03725 0.124 0.057 DBMET03727 0.112 0.07 DBMET03728 0.207 0.025 DBMET03729 0.113 0.068 DBMET03726 | ||
| 0.266 | 0.045 | 0.266 | Sigma receptor agonist | 0.175 0.071 DBMET03723 0.221 0.055 DBMET03725 0.136 0.096 DBMET03727 0.133 0.099 DBMET03728 0.161 0.078 DBMET03724 | ||
| 0.278 | 0.078 | 0.455 | Hypoxia-inducible factor 1 alpha inhibitor | 0.207 0.144 DBMET03723 0.27 0.083 DBMET03725 0.242 0.108 DBMET03727 0.455 0.019 DBMET03729 0.445 0.021 DBMET03726 | DBMET03729 | |
| 0.193 | 0.004 | 0.193 | Glutamate (mGluR group I) agonist | 0.073 0.015 DBMET03723 0.096 0.009 DBMET03725 0.089 0.01 DBMET03727 0.051 0.029 DBMET03728 0.096 0.009 DBMET03729 0.048 0.033 DBMET03724 0.047 0.034 DBMET03726 | ||
| 0.196 | 0.015 | 0.196 | Histamine H1 receptor antagonist | 0.082 0.055 DBMET03723 0.078 0.059 DBMET03725 0.108 0.037 DBMET03727 0.115 0.034 DBMET03729 | ||
| 0.194 | 0.015 | 0.239 | Alpha 2a adrenoreceptor antagonist | 0.073 0.054 DBMET03723 0.125 0.028 DBMET03725 0.125 0.028 DBMET03727 0.239 0.01 DBMET03729 0.163 0.02 DBMET03726 | DBMET03729 | |
| 0.171 | 0.008 | 0.171 | Dopamine D4 agonist | 0.048 0.037 DBMET03723 0.075 0.021 DBMET03725 0.06 0.027 DBMET03727 0.045 0.042 DBMET03728 0.087 0.018 DBMET03729 | ||
| 0.183 | 0.022 | 0.19 | GABA receptor agonist | 0.118 0.058 DBMET03725 0.097 0.081 DBMET03727 0.19 0.02 DBMET03728 0.148 0.037 DBMET03729 0.091 0.088 DBMET03726 | DBMET03728 | |
| 0.174 | 0.015 | 0.174 | 5 Hydroxytryptamine 7 antagonist | 0.058 0.047 DBMET03723 0.074 0.034 DBMET03725 0.056 0.049 DBMET03727 0.133 0.02 DBMET03729 | ||
| 0.161 | 0.004 | 0.161 | Glutamate (mGluR5) agonist | 0.072 0.013 DBMET03723 0.088 0.009 DBMET03725 0.084 0.01 DBMET03727 0.05 0.026 DBMET03728 0.094 0.008 DBMET03729 0.047 0.03 DBMET03724 0.045 0.033 DBMET03726 | ||
| 0.164 | 0.01 | 0.164 | Acetylcholine release stimulant | 0.109 0.069 DBMET03723 0.098 0.092 DBMET03725 0.121 0.047 DBMET03727 0.1 0.088 DBMET03728 0.14 0.024 DBMET03729 | ||
| 0.281 | 0.129 | 0.492 | GABA C receptor rho-3 antagonist | 0.283 0.128 DBMET03725 0.491 0.028 DBMET03729 0.492 0.028 DBMET03726 | DBMET03726 | |
| 0.167 | 0.014 | 0.167 | Glutamate receptor agonist | 0.069 0.064 DBMET03723 0.107 0.033 DBMET03725 0.126 0.024 DBMET03727 0.087 0.047 DBMET03729 | ||
| 0.314 | 0.166 | 0.331 | MAP kinase 1 inhibitor | 0.331 0.15 DBMET03729 | DBMET03729 | |
| 0.16 | 0.015 | 0.162 | 5 Hydroxytryptamine 1F antagonist | 0.09 0.037 DBMET03725 0.077 0.045 DBMET03727 0.162 0.014 DBMET03729 | DBMET03729 | |
| 0.177 | 0.033 | 0.177 | Nav1.3 sodium channel blocker | 0.128 0.066 DBMET03725 0.139 0.055 DBMET03727 0.111 0.084 DBMET03728 0.169 0.037 DBMET03729 0.121 0.073 DBMET03726 | ||
| 0.221 | 0.079 | 0.312 | HERG channel blocker | 0.312 0.046 DBMET03729 | DBMET03729 | |
| 0.249 | 0.109 | 0.36 | Nootropic | 0.185 0.18 DBMET03727 0.36 0.051 DBMET03729 | DBMET03729 | |
| 0.171 | 0.034 | 0.201 | Adenylate cyclase stimulant | 0.186 0.021 DBMET03723 0.174 0.031 DBMET03725 0.187 0.021 DBMET03727 0.148 0.066 DBMET03728 0.198 0.014 DBMET03729 0.175 0.03 DBMET03724 0.201 0.013 DBMET03726 | DBMET03726 | |
| 0.161 | 0.029 | 0.161 | Calcium channel (voltage-sensitive) blocker | 0.1 0.084 DBMET03723 0.109 0.072 DBMET03725 | ||
| 0.156 | 0.025 | 0.156 | 5 Hydroxytryptamine 2C antagonist | 0.136 0.03 DBMET03729 | ||
| 0.157 | 0.031 | 0.188 | Heat shock protein 70 antagonist | 0.15 0.046 DBMET03723 0.144 0.062 DBMET03725 0.147 0.053 DBMET03727 0.133 0.105 DBMET03728 0.188 0.009 DBMET03729 0.133 0.106 DBMET03724 0.169 0.018 DBMET03726 | DBMET03729 | |
| 0.132 | 0.011 | 0.171 | Caspase 7 inhibitor | 0.121 0.014 DBMET03725 0.093 0.037 DBMET03727 0.085 0.05 DBMET03728 0.171 0.005 DBMET03729 0.161 0.005 DBMET03726 | DBMET03729 | |
| 0.15 | 0.032 | 0.166 | Antihistaminic | 0.166 0.028 DBMET03729 | DBMET03729 | |
| 0.143 | 0.031 | 0.16 | Histamine antagonist | 0.16 0.027 DBMET03729 | DBMET03729 | |
| 0.161 | 0.05 | 0.161 | Calcium channel blocker | 0.111 0.098 DBMET03727 | ||
| 0.202 | 0.094 | 0.256 | Potassium channel (Voltage-sensitive) blocker | 0.256 0.064 DBMET03729 | DBMET03729 | |
| 0.144 | 0.038 | 0.247 | 5 Hydroxytryptamine 3A agonist | 0.116 0.059 DBMET03725 0.247 0.005 DBMET03729 0.221 0.01 DBMET03726 | DBMET03729 | |
| 0.207 | 0.103 | 0.207 | Tumour necrosis factor alpha release inhibitor | 0.196 0.112 DBMET03727 | ||
| 0.285 | 0.182 | 0.329 | 5 Hydroxytryptamine release inhibitor | 0.268 0.204 DBMET03725 0.329 0.134 DBMET03729 0.311 0.153 DBMET03726 | DBMET03729 | |
| 0.12 | 0.018 | 0.12 | Phosphodiesterase 4B inhibitor | 0.06 0.056 DBMET03729 | ||
| 0.104 | 0.004 | 0.104 | Delayed rectifier potassium channel blocker | 0.061 0.007 DBMET03723 0.077 0.004 DBMET03725 0.048 0.013 DBMET03727 0.04 0.021 DBMET03728 0.037 0.027 DBMET03729 0.051 0.011 DBMET03724 | ||
| 0.16 | 0.066 | 0.16 | Acetylcholine M1 receptor antagonist | 0.142 0.083 DBMET03723 0.137 0.088 DBMET03725 0.12 0.108 DBMET03724 | ||
| 0.16 | 0.067 | 0.16 | Interferon gamma antagonist | 0.149 0.079 DBMET03723 0.159 0.067 DBMET03725 0.149 0.08 DBMET03727 0.13 0.112 DBMET03728 0.138 0.095 DBMET03729 0.135 0.102 DBMET03724 0.138 0.096 DBMET03726 | ||
| 0.106 | 0.014 | 0.106 | Calcium channel T-type blocker | 0.063 0.033 DBMET03725 0.061 0.036 DBMET03728 | ||
| 0.115 | 0.025 | 0.152 | Glutamate release inhibitor | 0.091 0.06 DBMET03723 0.109 0.031 DBMET03725 0.11 0.03 DBMET03727 0.152 0.009 DBMET03729 0.09 0.061 DBMET03724 0.143 0.012 DBMET03726 | DBMET03729 | |
| 0.109 | 0.022 | 0.109 | Acetylcholine M4 receptor antagonist | 0.093 0.034 DBMET03727 0.093 0.034 DBMET03729 | ||
| 0.108 | 0.024 | 0.108 | Dopamine agonist | 0.104 0.026 DBMET03725 0.067 0.046 DBMET03729 0.065 0.048 DBMET03726 | ||
| 0.147 | 0.065 | 0.234 | Toll-Like receptor 9 antagonist | 0.234 0.024 DBMET03729 0.15 0.063 DBMET03726 | DBMET03729 | |
| 0.14 | 0.058 | 0.146 | Cholinergic antagonist | 0.146 0.055 DBMET03725 0.117 0.076 DBMET03727 | DBMET03725 | |
| 0.137 | 0.058 | 0.143 | Acetylcholine antagonist | 0.143 0.054 DBMET03725 0.114 0.076 DBMET03727 | DBMET03725 | |
| 0.083 | 0.007 | 0.085 | Alpha 1L adrenoreceptor antagonist | 0.066 0.016 DBMET03723 0.073 0.011 DBMET03725 0.065 0.016 DBMET03727 0.085 0.006 DBMET03729 0.063 0.019 DBMET03724 0.068 0.014 DBMET03726 | DBMET03729 | |
| 0.099 | 0.024 | 0.099 | 5 Hydroxytryptamine 1B antagonist | 0.077 0.036 DBMET03729 | ||
| 0.099 | 0.028 | 0.099 | Lipase inhibitor | 0.08 0.043 DBMET03723 0.092 0.032 DBMET03725 0.073 0.05 DBMET03727 0.074 0.05 DBMET03724 | ||
| 0.075 | 0.005 | 0.075 | Nerve growth factor antagonist | 0.046 0.023 DBMET03723 0.066 0.006 DBMET03725 0.051 0.017 DBMET03727 0.052 0.016 DBMET03728 0.062 0.008 DBMET03729 0.039 0.038 DBMET03724 0.054 0.014 DBMET03726 | ||
| 0.089 | 0.021 | 0.262 | 5 Hydroxytryptamine 3 agonist | 0.058 0.052 DBMET03725 0.262 0.003 DBMET03729 0.167 0.004 DBMET03726 | DBMET03729 | |
| 0.09 | 0.023 | 0.168 | 5 Hydroxytryptamine 3A antagonist | 0.168 0.004 DBMET03729 0.087 0.025 DBMET03726 | DBMET03729 | |
| 0.086 | 0.019 | 0.086 | Sigma receptor antagonist | 0.055 0.031 DBMET03725 | ||
| 0.211 | 0.145 | 0.463 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.307 0.059 DBMET03728 0.463 0.011 DBMET03729 0.405 0.02 DBMET03726 | DBMET03729 | |
| 0.165 | 0.1 | 0.236 | MAP kinase kinase 5 inhibitor | 0.236 0.01 DBMET03729 0.21 0.023 DBMET03726 | DBMET03729 | |
| 0.083 | 0.019 | 0.089 | Heat shock protein 90 beta antagonist | 0.089 0.015 DBMET03725 0.082 0.019 DBMET03729 0.088 0.016 DBMET03726 | DBMET03725 | |
| 0.175 | 0.116 | 0.306 | Cyclic AMP phosphodiesterase inhibitor | 0.17 0.123 DBMET03727 0.306 0.039 DBMET03729 0.266 0.056 DBMET03726 | DBMET03729 | |
| 0.103 | 0.043 | 0.103 | Phosphodiesterase IV inhibitor | 0.077 0.064 DBMET03727 0.09 0.053 DBMET03729 | ||
| 0.082 | 0.023 | 0.139 | 5 Hydroxytryptamine 3 antagonist | 0.139 0.01 DBMET03729 | DBMET03729 | |
| 0.097 | 0.04 | 0.11 | GABA A receptor agonist | 0.11 0.03 DBMET03729 | DBMET03729 | |
| 0.129 | 0.073 | 0.139 | Nav1.2 sodium channel blocker | 0.139 0.065 DBMET03727 0.11 0.096 DBMET03729 | DBMET03727 | |
| 0.067 | 0.012 | 0.07 | Dopamine D3 agonist | 0.036 0.032 DBMET03723 0.07 0.011 DBMET03725 0.044 0.023 DBMET03727 0.043 0.025 DBMET03724 0.036 0.032 DBMET03726 | DBMET03725 | |
| 0.083 | 0.031 | 0.114 | Orexin receptor 1 antagonist | 0.114 0.007 DBMET03729 0.071 0.051 DBMET03726 | DBMET03729 | |
| 0.119 | 0.068 | 0.119 | Acetylcholine muscarinic antagonist | 0.097 0.094 DBMET03723 0.097 0.095 DBMET03725 0.119 0.068 DBMET03727 | ||
| 0.103 | 0.053 | 0.152 | Interleukin 1 beta converting enzyme inhibitor | 0.105 0.051 DBMET03725 0.15 0.017 DBMET03729 0.152 0.016 DBMET03726 | DBMET03726 | |
| 0.117 | 0.067 | 0.125 | Calcium channel N-type blocker | 0.125 0.057 DBMET03729 | DBMET03729 | |
| 0.113 | 0.067 | 0.139 | TRPA1 agonist | 0.11 0.071 DBMET03725 0.139 0.04 DBMET03729 0.135 0.043 DBMET03726 | DBMET03729 | |
| 0.088 | 0.042 | 0.088 | Phosphodiesterase 4D inhibitor | |||
| 0.085 | 0.039 | 0.15 | Polo-like kinase-2 inhibitor | 0.07 0.053 DBMET03725 0.063 0.062 DBMET03727 0.15 0.004 DBMET03729 0.132 0.005 DBMET03726 | DBMET03729 | |
| 0.128 | 0.093 | 0.159 | Cytidine deaminase inhibitor | 0.159 0.069 DBMET03728 0.135 0.087 DBMET03729 | DBMET03728 | |
| 0.179 | 0.143 | 0.414 | Superoxide dismutase inhibitor | 0.178 0.144 DBMET03725 0.414 0.024 DBMET03729 0.412 0.025 DBMET03726 | DBMET03729 | |
| 0.056 | 0.022 | 0.056 | Cholesterol esterase inhibitor | 0.049 0.031 DBMET03725 | ||
| 0.072 | 0.039 | 0.086 | Bcl2 antagonist | 0.086 0.027 DBMET03725 | DBMET03725 | |
| 0.122 | 0.092 | 0.154 | Nav1.6 sodium channel blocker | 0.118 0.1 DBMET03727 0.154 0.049 DBMET03729 0.121 0.094 DBMET03726 | DBMET03729 | |
| 0.129 | 0.099 | 0.129 | Heat shock protein 90 antagonist | |||
| 0.07 | 0.041 | 0.11 | Orexin receptor antagonist | 0.11 0.009 DBMET03729 | DBMET03729 | |
| 0.042 | 0.013 | 0.042 | CXC chemokine 3 receptor antagonist | |||
| 0.058 | 0.03 | 0.149 | Histamine agonist | 0.149 0.005 DBMET03729 0.066 0.022 DBMET03726 | DBMET03729 | |
| 0.068 | 0.042 | 0.072 | Dopamine D1 antagonist | 0.072 0.039 DBMET03725 0.057 0.054 DBMET03727 | DBMET03725 | |
| 0.095 | 0.072 | 0.183 | Nav1.1 sodium channel blocker | 0.183 0.023 DBMET03727 0.148 0.034 DBMET03728 | DBMET03727 | |
| 0.071 | 0.048 | 0.115 | CXC chemokine receptor antagonist | 0.115 0.019 DBMET03729 | DBMET03729 | |
| 0.07 | 0.048 | 0.126 | Protein kinase C beta inhibitor | 0.071 0.046 DBMET03727 0.066 0.057 DBMET03728 0.126 0.006 DBMET03729 0.111 0.009 DBMET03726 | DBMET03729 | |
| 0.095 | 0.076 | 0.186 | Ferrochelatase inhibitor | 0.186 0.026 DBMET03729 0.129 0.048 DBMET03726 | DBMET03729 | |
| 0.046 | 0.028 | 0.066 | Geranyltranstransferase inhibitor | 0.066 0.009 DBMET03729 0.053 0.02 DBMET03726 | DBMET03729 | |
| 0.039 | 0.022 | 0.068 | Orexin receptor 2 antagonist | 0.068 0.008 DBMET03729 | DBMET03729 | |
| 0.03 | 0.013 | 0.042 | Dopamine autoreceptor agonist | 0.042 0.009 DBMET03729 | DBMET03729 | |
| 0.082 | 0.065 | 0.13 | Histamine N-methyltransferase inhibitor | 0.13 0.023 DBMET03729 0.097 0.048 DBMET03726 | DBMET03729 | |
| 0.041 | 0.025 | 0.188 | Vascular adhesion protein 1 inhibitor | 0.188 0.003 DBMET03729 0.09 0.004 DBMET03726 | DBMET03729 | |
| 0.131 | 0.115 | 0.145 | Ca2+-transporting ATPase inhibitor | 0.135 0.093 DBMET03723 0.137 0.087 DBMET03725 0.139 0.079 DBMET03729 0.135 0.095 DBMET03724 0.145 0.058 DBMET03726 | DBMET03726 | |
| 0.058 | 0.043 | 0.071 | Ca(v)3.2 blocker | 0.071 0.022 DBMET03729 0.055 0.05 DBMET03726 | DBMET03729 | |
| 0.06 | 0.045 | 0.06 | Acetylcholine M2 receptor antagonist | |||
| 0.121 | 0.106 | 0.121 | Cholinergic | |||
| 0.104 | 0.09 | 0.121 | Sphingosine 1-phosphate receptor 2 agonist | 0.121 0.054 DBMET03729 0.111 0.073 DBMET03726 | DBMET03729 | |
| 0.197 | 0.184 | 0.29 | Apoptosis antagonist | 0.278 0.101 DBMET03723 0.245 0.133 DBMET03725 0.263 0.115 DBMET03727 0.199 0.181 DBMET03728 0.29 0.092 DBMET03724 | DBMET03724 | |
| 0.067 | 0.056 | 0.068 | Telomerase inhibitor | 0.068 0.054 DBMET03729 | DBMET03729 | |
| 0.06 | 0.049 | 0.074 | 5 Hydroxytryptamine 1D antagonist | 0.074 0.035 DBMET03729 | DBMET03729 | |
| 0.071 | 0.06 | 0.138 | Nicotinic alpha4beta2 receptor antagonist | 0.138 0.01 DBMET03729 0.121 0.017 DBMET03726 | DBMET03729 | |
| 0.08 | 0.069 | 0.128 | mTOR complex 2 inhibitor | 0.128 0.014 DBMET03729 0.123 0.016 DBMET03726 | DBMET03729 | |
| 0.023 | 0.014 | 0.023 | Retinoic acid gamma receptor agonist | 0.023 0.015 DBMET03725 0.022 0.015 DBMET03727 | ||
| 0.073 | 0.064 | 0.107 | Acetylcholine nicotinic antagonist | 0.107 0.035 DBMET03729 0.085 0.05 DBMET03726 | DBMET03729 | |
| 0.047 | 0.038 | 0.09 | Potassium channel (Inward rectifier) blocker | 0.09 0.009 DBMET03729 0.067 0.019 DBMET03726 | DBMET03729 | |
| 0.066 | 0.057 | 0.066 | Calcium channel L-type blocker | |||
| 0.077 | 0.069 | 0.078 | Ca(v)3.1 blocker | 0.078 0.067 DBMET03725 | DBMET03725 | |
| 0.138 | 0.129 | 0.241 | DNA methylase inhibitor | 0.241 0.053 DBMET03729 0.189 0.087 DBMET03726 | DBMET03729 | |
| 0.027 | 0.018 | 0.027 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.025 0.024 DBMET03723 0.026 0.022 DBMET03725 0.025 0.023 DBMET03727 | ||
| 0.059 | 0.05 | 0.064 | Heme oxygenase stimulant | 0.064 0.035 DBMET03725 0.057 0.054 DBMET03728 | DBMET03725 | |
| 0.083 | 0.075 | 0.121 | Polo-like kinase-1 inhibitor | 0.121 0.029 DBMET03729 0.101 0.044 DBMET03726 | DBMET03729 | |
| 0.041 | 0.033 | 0.055 | Dopamine D2 agonist | 0.055 0.023 DBMET03725 | DBMET03725 | |
| 0.074 | 0.067 | 0.144 | Adrenaline agonist | 0.082 0.055 DBMET03725 0.081 0.056 DBMET03727 0.133 0.02 DBMET03729 0.144 0.016 DBMET03726 | DBMET03726 | |
| 0.02 | 0.016 | 0.02 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.068 | 0.066 | 0.086 | Phosphodiesterase VI inhibitor | 0.086 0.033 DBMET03729 | DBMET03729 | |
| 0.083 | 0.081 | 0.16 | Creatine kinase inhibitor | 0.087 0.077 DBMET03723 0.151 0.024 DBMET03725 0.09 0.071 DBMET03729 0.124 0.038 DBMET03724 0.16 0.02 DBMET03726 | DBMET03726 | |
| 0.033 | 0.032 | 0.033 | Adenosine uptake inhibitor | |||
| 0.028 | 0.029 | 0.032 | Potassium channel (Inward rectifier) 1 blocker | 0.032 0.016 DBMET03729 | DBMET03729 | |
| 0.043 | 0.045 | 0.118 | Histamine H4 receptor antagonist | 0.118 0.004 DBMET03729 0.065 0.015 DBMET03726 | DBMET03729 | |
| 0.077 | 0.078 | 0.09 | Transforming growth factor beta 3 antagonist | 0.09 0.038 DBMET03729 | DBMET03729 | |
| 0.013 | 0.015 | 0.018 | CXC chemokine 4 receptor agonist | 0.018 0.007 DBMET03729 | DBMET03729 | |
| 0.043 | 0.047 | 0.044 | Phosphodiesterase 6C inhibitor | 0.044 0.041 DBMET03729 | DBMET03729 | |
| 0.029 | 0.033 | 0.042 | Vanilloid 4 antagonist | 0.042 0.01 DBMET03729 0.033 0.022 DBMET03726 | DBMET03729 | |
| 0.035 | 0.04 | 0.038 | Thymidine kinase inhibitor | 0.038 0.034 DBMET03728 | DBMET03728 | |
| 0.018 | 0.023 | 0.034 | Glutaminyl-peptide cyclotransferase inhibitor | 0.034 0.005 DBMET03729 | DBMET03729 | |
| 0.028 | 0.034 | 0.047 | Glucose-dependent insulinotropic receptor agonist | 0.047 0.013 DBMET03729 0.04 0.017 DBMET03726 | DBMET03729 | |
| 0.011 | 0.017 | 0.023 | Cyclin D2 inhibitor | 0.023 0.003 DBMET03729 0.016 0.005 DBMET03726 | DBMET03729 | |
| 0.13 | 0.137 | 0.238 | Anesthetic general | 0.155 0.109 DBMET03728 0.238 0.056 DBMET03729 0.172 0.093 DBMET03726 | DBMET03729 | |
| 0.04 | 0.047 | 0.074 | CC chemokine 4 receptor antagonist | 0.074 0.009 DBMET03729 0.05 0.027 DBMET03726 | DBMET03729 | |
| 0.14 | 0.147 | 0.238 | Focal adhesion kinase 2 inhibitor | 0.238 0.044 DBMET03729 0.2 0.069 DBMET03726 | DBMET03729 | |
| 0.141 | 0.152 | 0.187 | Neurotrophic factor enhancer | 0.186 0.091 DBMET03725 0.162 0.121 DBMET03727 0.159 0.125 DBMET03724 0.187 0.09 DBMET03726 | DBMET03726 | |
| 0.053 | 0.064 | 0.103 | Neuronal nicotinic receptor antagonist | 0.103 0.023 DBMET03729 0.082 0.035 DBMET03726 | DBMET03729 | |
| 0.038 | 0.049 | 0.059 | Purinergic P2X antagonist | 0.059 0.024 DBMET03729 | DBMET03729 | |
| 0.048 | 0.059 | 0.055 | 5 Hydroxytryptamine 7 agonist | 0.055 0.041 DBMET03729 | DBMET03729 | |
| 0.047 | 0.06 | 0.139 | Cyclin-dependent kinase 6 inhibitor | 0.139 0.005 DBMET03729 0.102 0.009 DBMET03726 | DBMET03729 | |
| 0.056 | 0.07 | 0.131 | Phosphodiesterase V inhibitor | 0.131 0.015 DBMET03729 0.074 0.048 DBMET03726 | DBMET03729 | |
| 0.056 | 0.071 | 0.129 | Phosphodiesterase 5A inhibitor | 0.129 0.016 DBMET03729 0.069 0.051 DBMET03726 | DBMET03729 | |
| 0.027 | 0.042 | 0.064 | 5 Hydroxytryptamine 3B antagonist | 0.064 0.01 DBMET03729 | DBMET03729 | |
| 0.045 | 0.06 | 0.265 | CXC chemokine 4 receptor antagonist | 0.265 0.006 DBMET03729 0.096 0.025 DBMET03726 | DBMET03729 | |
| 0.045 | 0.061 | 0.113 | Glucosylceramidase inhibitor | 0.066 0.025 DBMET03723 0.051 0.045 DBMET03727 0.051 0.046 DBMET03728 0.113 0.006 DBMET03729 0.099 0.008 DBMET03726 | DBMET03729 | |
| 0.02 | 0.036 | 0.03 | Acetylcholine M4 receptor agonist | 0.03 0.022 DBMET03729 | DBMET03729 | |
| 0.029 | 0.047 | 0.056 | Histamine H3 receptor antagonist | 0.056 0.023 DBMET03729 | DBMET03729 | |
| 0.043 | 0.062 | 0.082 | 5 Hydroxytryptamine 1B agonist | 0.082 0.011 DBMET03729 0.055 0.033 DBMET03726 | DBMET03729 | |
| 0.037 | 0.057 | 0.073 | Dipeptidyl peptidase IV inhibitor | 0.073 0.009 DBMET03729 0.041 0.04 DBMET03726 | DBMET03729 | |
| 0.068 | 0.088 | 0.121 | Acetylcholine agonist | 0.121 0.036 DBMET03729 | DBMET03729 | |
| 0.121 | 0.142 | 0.225 | Tumour necrosis factor antagonist | 0.225 0.04 DBMET03729 0.188 0.061 DBMET03726 | DBMET03729 | |
| 0.026 | 0.046 | 0.043 | CDK6/cyclin D3 inhibitor | 0.043 0.01 DBMET03729 0.034 0.023 DBMET03726 | DBMET03729 | |
| 0.043 | 0.066 | 0.092 | Sphingosine kinase 2 inhibitor | 0.057 0.036 DBMET03727 0.092 0.01 DBMET03729 0.092 0.01 DBMET03726 | DBMET03726 | |
| 0.035 | 0.058 | 0.061 | Poly(ADP-ribose) polymerase inhibitor | 0.061 0.016 DBMET03729 | DBMET03729 | |
| 0.083 | 0.106 | 0.096 | mTOR complex 1 inhibitor | 0.096 0.071 DBMET03729 | DBMET03729 | |
| 0.058 | 0.082 | 0.091 | Phospholipase D inhibitor | 0.091 0.021 DBMET03729 0.075 0.043 DBMET03726 | DBMET03729 | |
| 0.01 | 0.037 | 0.075 | Histamine H4 receptor agonist | 0.075 0.004 DBMET03729 0.027 0.008 DBMET03726 | DBMET03729 | |
| 0.119 | 0.147 | 0.147 | Antipruritic | 0.147 0.098 DBMET03729 | DBMET03729 | |
| 0.065 | 0.093 | 0.159 | Inducible nitric-oxide synthase inhibitor | 0.159 0.014 DBMET03729 0.09 0.047 DBMET03726 | DBMET03729 | |
| 0.028 | 0.057 | 0.04 | Glutamate (mGluR1a) antagonist | 0.04 0.03 DBMET03729 | DBMET03729 | |
| 0.042 | 0.072 | 0.08 | Carbamoyl phosphate synthetase inhibitor | 0.053 0.052 DBMET03723 0.065 0.038 DBMET03729 0.08 0.028 DBMET03726 | DBMET03726 | |
| 0.126 | 0.157 | 0.162 | P-glycoprotein inhibitor | 0.162 0.099 DBMET03723 0.148 0.121 DBMET03724 | DBMET03723 | |
| 0.03 | 0.064 | 0.053 | Sphingosine kinase 1 inhibitor | 0.039 0.034 DBMET03727 0.051 0.016 DBMET03729 0.053 0.013 DBMET03726 | DBMET03726 | |
| 0.024 | 0.058 | 0.036 | p53 inhibitor | 0.036 0.024 DBMET03727 | DBMET03727 | |
| 0.045 | 0.079 | 0.08 | Sphingosine kinase inhibitor | 0.057 0.045 DBMET03727 0.076 0.019 DBMET03729 0.08 0.016 DBMET03726 | DBMET03726 | |
| 0.014 | 0.05 | 0.043 | Poly(ADP-ribose) polymerase 2 inhibitor | 0.043 0.01 DBMET03729 | DBMET03729 | |
| 0.063 | 0.099 | 0.078 | Viral attachment inhibitor | 0.078 0.054 DBMET03729 0.073 0.066 DBMET03726 | DBMET03729 | |
| 0.023 | 0.06 | 0.035 | DNA topoisomerase IV inhibitor | 0.035 0.013 DBMET03729 | DBMET03729 | |
| 0.089 | 0.126 | 0.15 | Phosphodiesterase inhibitor | 0.15 0.058 DBMET03729 | DBMET03729 | |
| 0.024 | 0.062 | 0.046 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.046 0.019 DBMET03729 | DBMET03729 | |
| 0.071 | 0.109 | 0.079 | CC chemokine 5 receptor agonist | 0.078 0.074 DBMET03729 0.079 0.068 DBMET03726 | DBMET03726 | |
| 0.02 | 0.058 | 0.047 | G protein-coupled receptor agonist | 0.046 0.02 DBMET03729 0.047 0.019 DBMET03726 | DBMET03726 | |
| 0.076 | 0.114 | 0.102 | Interleukin 12 antagonist | 0.089 0.075 DBMET03729 0.102 0.051 DBMET03726 | DBMET03726 | |
| 0.04 | 0.079 | 0.081 | Dipeptidyl peptidase inhibitor | 0.081 0.013 DBMET03729 | DBMET03729 | |
| 0.01 | 0.051 | 0.025 | Complement factor D inhibitor | 0.025 0.005 DBMET03729 | DBMET03729 | |
| 0.069 | 0.11 | 0.089 | ATPase (Vacuolar H+) inhibitor | 0.089 0.057 DBMET03723 0.082 0.072 DBMET03724 | DBMET03723 | |
| 0.026 | 0.068 | 0.041 | Oleamide hydrolase inhibitor | 0.041 0.037 DBMET03729 | DBMET03729 | |
| 0.073 | 0.115 | 0.162 | Nitric-oxide synthase inhibitor | 0.162 0.018 DBMET03729 0.096 0.066 DBMET03726 | DBMET03729 | |
| 0.08 | 0.122 | 0.159 | Beta amyloid protein antagonist | 0.159 0.035 DBMET03729 0.133 0.054 DBMET03726 | DBMET03729 | |
| 0.033 | 0.079 | 0.051 | Acetylcholine muscarinic agonist | 0.051 0.042 DBMET03729 | DBMET03729 | |
| 0.038 | 0.085 | 0.056 | Purinergic P2 antagonist | 0.056 0.052 DBMET03729 | DBMET03729 | |
| 0.026 | 0.075 | 0.186 | Janus tyrosine kinase 1 inhibitor | 0.186 0.005 DBMET03729 | DBMET03729 | |
| 0.077 | 0.126 | 0.178 | Protein kinase C gamma inhibitor | 0.178 0.019 DBMET03729 0.169 0.023 DBMET03726 | DBMET03729 | |
| 0.039 | 0.088 | 0.051 | Nicotinic alpha3beta2 receptor antagonist | 0.051 0.041 DBMET03729 | DBMET03729 | |
| 0.022 | 0.072 | 0.039 | Ceramide glucosyltransferase inhibitor | 0.039 0.019 DBMET03727 | DBMET03727 | |
| 0.011 | 0.062 | 0.033 | 5 Hydroxytryptamine 1D agonist | 0.033 0.017 DBMET03729 | DBMET03729 | |
| 0.003 | 0.054 | 0.013 | Melatonin 5 antagonist | 0.013 0.007 DBMET03729 | DBMET03729 | |
| 0.048 | 0.102 | 0.161 | Protein kinase B beta inhibitor | 0.161 0.006 DBMET03729 0.116 0.017 DBMET03726 | DBMET03729 | |
| 0.03 | 0.085 | 0.097 | Potassium channel small-conductance Ca-activated blocker | 0.097 0.007 DBMET03729 0.046 0.029 DBMET03726 | DBMET03729 | |
| 0.029 | 0.088 | 0.063 | Histamine H1 receptor agonist | 0.063 0.007 DBMET03729 0.041 0.038 DBMET03726 | DBMET03729 | |
| 0.044 | 0.103 | 0.061 | Phosphodiesterase 1A inhibitor | 0.061 0.038 DBMET03729 | DBMET03729 | |
| 0.066 | 0.126 | 0.232 | Polo-like kinase-4 inhibitor | 0.232 0.01 DBMET03729 0.19 0.018 DBMET03726 | DBMET03729 | |
| 0.043 | 0.102 | 0.3 | Janus tyrosine kinase 2 inhibitor | 0.3 0.005 DBMET03729 0.069 0.056 DBMET03726 | DBMET03729 | |
| 0.015 | 0.074 | 0.026 | LFA antagonist | 0.026 0.023 DBMET03729 | DBMET03729 | |
| 0.059 | 0.12 | 0.096 | Histamine H2 receptor antagonist | 0.096 0.039 DBMET03729 | DBMET03729 | |
| 0.02 | 0.08 | 0.076 | Cyclin D3 inhibitor | 0.076 0.011 DBMET03729 0.055 0.019 DBMET03726 | DBMET03729 | |
| 0.033 | 0.095 | 0.098 | Protein kinase C eta inhibitor | 0.098 0.018 DBMET03729 0.092 0.019 DBMET03726 | DBMET03729 | |
| 0.042 | 0.104 | 0.062 | Potassium channel (Ca-activated) blocker | 0.062 0.037 DBMET03729 | DBMET03729 | |
| 0.151 | 0.213 | 0.24 | 5 Hydroxytryptamine 3E antagonist | 0.24 0.021 DBMET03729 0.198 0.066 DBMET03726 | DBMET03729 | |
| 0.025 | 0.088 | 0.135 | Protein kinase (CK1) epsilon inhibitor | 0.135 0.004 DBMET03729 0.05 0.013 DBMET03726 | DBMET03729 | |
| 0.041 | 0.108 | 0.135 | Porphobilinogen synthase inhibitor | 0.114 0.03 DBMET03729 0.135 0.024 DBMET03726 | DBMET03726 | |
| 0.062 | 0.13 | 0.086 | Phosphodiesterase I inhibitor | 0.086 0.065 DBMET03729 | DBMET03729 | |
| 0.031 | 0.099 | 0.061 | Nicotinic alpha7 receptor agonist | 0.061 0.031 DBMET03729 | DBMET03729 | |
| 0.015 | 0.084 | 0.052 | Cholesterol ester transfer protein antagonist | 0.031 0.023 DBMET03729 0.052 0.006 DBMET03726 | DBMET03726 | |
| 0.158 | 0.229 | 0.266 | Vasodilator, coronary | 0.214 0.169 DBMET03727 0.252 0.132 DBMET03729 0.195 0.186 DBMET03724 0.266 0.119 DBMET03726 | DBMET03726 | |
| 0.032 | 0.103 | 0.112 | 5 Hydroxytryptamine 2A agonist | 0.112 0.011 DBMET03729 0.097 0.016 DBMET03726 | DBMET03729 | |
| 0.144 | 0.217 | 0.292 | DNA synthesis inhibitor | 0.172 0.165 DBMET03725 0.221 0.093 DBMET03727 0.205 0.116 DBMET03728 0.258 0.061 DBMET03729 0.292 0.046 DBMET03726 | DBMET03726 | |
| 0.023 | 0.097 | 0.263 | Tyk2 inhibitor | 0.263 0.005 DBMET03729 0.105 0.026 DBMET03726 | DBMET03729 | |
| 0.082 | 0.158 | 0.195 | Toll-Like receptor antagonist | 0.195 0.032 DBMET03729 0.161 0.048 DBMET03726 | DBMET03729 | |
| 0.046 | 0.122 | 0.091 | Secretase beta inhibitor | 0.091 0.024 DBMET03729 0.075 0.043 DBMET03726 | DBMET03729 | |
| 0.086 | 0.164 | 0.141 | Antibacterial (Helicobacter pylori) | 0.141 0.055 DBMET03729 | DBMET03729 | |
| 0.025 | 0.104 | 0.066 | 5 Hydroxytryptamine uptake inhibitor | 0.066 0.042 DBMET03729 | DBMET03729 | |
| 0.041 | 0.12 | 0.066 | Corticotropin releasing factor 2 receptor antagonist | 0.066 0.034 DBMET03729 | DBMET03729 | |
| 0.049 | 0.128 | 0.081 | Potassium channel (Tandem pore domain) blocker | 0.081 0.032 DBMET03729 | DBMET03729 | |
| 0.082 | 0.162 | 0.298 | Activin receptor-like kinase 2 inhibitor | 0.298 0.013 DBMET03729 0.225 0.027 DBMET03726 | DBMET03729 | |
| 0.039 | 0.119 | 0.073 | Amidase inhibitor | 0.073 0.045 DBMET03729 0.067 0.053 DBMET03726 | DBMET03729 | |
| 0.036 | 0.118 | 0.061 | Fibroblast growth factor 2 antagonist | 0.061 0.05 DBMET03729 | DBMET03729 | |
| 0.032 | 0.115 | 0.162 | Toll-Like receptor 7 antagonist | 0.162 0.005 DBMET03729 0.087 0.031 DBMET03726 | DBMET03729 | |
| 0.013 | 0.095 | 0.022 | Granulocyte colony stimulating factor receptor agonist | 0.022 0.006 DBMET03729 0.018 0.015 DBMET03726 | DBMET03729 | |
| 0.004 | 0.088 | 0.014 | Egl nine homolog 3 inhibitor | 0.014 0.006 DBMET03729 | DBMET03729 | |
| 0.043 | 0.129 | 0.088 | Glutamate (mGluR7) antagonist | 0.088 0.019 DBMET03729 | DBMET03729 | |
| 0.054 | 0.14 | 0.074 | Estrogen receptor alpha antagonist | 0.074 0.059 DBMET03726 | DBMET03726 | |
| 0.042 | 0.129 | 0.067 | Interferon inducer | 0.067 0.039 DBMET03726 | DBMET03726 | |
| 0.054 | 0.141 | 0.188 | Protein kinase C delta inhibitor | 0.188 0.01 DBMET03729 0.166 0.015 DBMET03726 | DBMET03729 | |
| 0.016 | 0.105 | 0.027 | Thymidine phosphorylase inhibitor | 0.027 0.016 DBMET03729 0.027 0.017 DBMET03726 | DBMET03726 | |
| 0.029 | 0.119 | 0.105 | Nicotinic receptor alpha4 subunit antagonist | 0.087 0.011 DBMET03729 0.105 0.007 DBMET03726 | DBMET03726 | |
| 0.053 | 0.144 | 0.072 | Vanilloid 4 agonist | 0.072 0.058 DBMET03729 | DBMET03729 | |
| 0.096 | 0.19 | 0.196 | GABA C receptor rho-2 antagonist | 0.196 0.031 DBMET03729 0.183 0.04 DBMET03726 | DBMET03729 | |
| 0.021 | 0.115 | 0.035 | Protein kinase C beta I inhibitor | 0.034 0.02 DBMET03729 0.035 0.018 DBMET03726 | DBMET03726 | |
| 0.03 | 0.125 | 0.286 | Alpha 2 adrenoreceptor agonist | 0.286 0.004 DBMET03729 0.176 0.005 DBMET03726 | DBMET03729 | |
| 0.015 | 0.11 | 0.052 | DNA gyrase subunit B inhibitor | 0.052 0.012 DBMET03729 0.035 0.032 DBMET03726 | DBMET03729 | |
| 0.027 | 0.123 | 0.072 | Acetylcholine M5 receptor agonist | 0.072 0.042 DBMET03729 | DBMET03729 | |
| 0.021 | 0.117 | 0.037 | Tryptophan 5 hydroxylase inhibitor | 0.037 0.02 DBMET03729 | DBMET03729 | |
| 0.028 | 0.128 | 0.068 | Dopamine beta hydroxylase inhibitor | 0.068 0.009 DBMET03729 0.064 0.011 DBMET03726 | DBMET03729 | |
| 0.004 | 0.103 | 0.015 | Egl nine homolog 1 inhibitor | 0.015 0.01 DBMET03726 | DBMET03726 | |
| 0.024 | 0.123 | 0.111 | Toll-Like receptor 8 antagonist | 0.111 0.006 DBMET03729 0.078 0.019 DBMET03726 | DBMET03729 | |
| 0.024 | 0.124 | 0.093 | Nicotinic neuronal receptor agonist | 0.093 0.015 DBMET03729 0.059 0.037 DBMET03726 | DBMET03729 | |
| 0.045 | 0.146 | 0.116 | Insulin like growth factor 1 antagonist | 0.116 0.031 DBMET03729 0.089 0.051 DBMET03726 | DBMET03729 | |
| 0.06 | 0.163 | 0.14 | Protein kinase C zeta inhibitor | 0.118 0.033 DBMET03729 0.14 0.023 DBMET03726 | DBMET03726 | |
| 0.026 | 0.13 | 0.06 | Biliverdin reductase inhibitor | 0.06 0.04 DBMET03729 0.052 0.05 DBMET03726 | DBMET03729 | |
| 0.042 | 0.146 | 0.209 | ALK inhibitor | 0.209 0.01 DBMET03729 0.131 0.025 DBMET03726 | DBMET03729 | |
| 0.009 | 0.113 | 0.035 | Endothelial nitric-oxide synthase inhibitor | 0.035 0.017 DBMET03729 | DBMET03729 | |
| 0.055 | 0.16 | 0.378 | GABA C receptor agonist | 0.341 0.007 DBMET03729 0.378 0.006 DBMET03726 | DBMET03726 | |
| 0.051 | 0.157 | 0.098 | Prolactin inhibitor | 0.083 0.076 DBMET03729 0.098 0.057 DBMET03726 | DBMET03726 | |
| 0.068 | 0.175 | 0.283 | Activin receptor-like kinase 4 inhibitor | 0.283 0.005 DBMET03729 0.155 0.026 DBMET03726 | DBMET03729 | |
| 0.041 | 0.149 | 0.151 | Acetylcholine nicotinic agonist | 0.151 0.017 DBMET03729 0.11 0.031 DBMET03726 | DBMET03729 | |
| 0.011 | 0.12 | 0.02 | Factor XIII inhibitor | 0.02 0.017 DBMET03729 | DBMET03729 | |
| 0.037 | 0.147 | 0.061 | 5 Hydroxytryptamine 5A antagonist | 0.061 0.043 DBMET03729 | DBMET03729 | |
| 0.117 | 0.228 | 0.222 | Cardiotonic | 0.222 0.101 DBMET03723 0.164 0.159 DBMET03724 | DBMET03723 | |
| 0.126 | 0.236 | 0.279 | MAP-kinase-activated kinase 5 inhibitor | 0.279 0.042 DBMET03729 0.227 0.076 DBMET03726 | DBMET03729 | |
| 0.042 | 0.153 | 0.123 | Insulin growth factor antagonist | 0.123 0.032 DBMET03729 0.097 0.048 DBMET03726 | DBMET03729 | |
| 0.024 | 0.135 | 0.222 | Janus tyrosine kinase 3 inhibitor | 0.222 0.009 DBMET03729 0.077 0.046 DBMET03726 | DBMET03729 | |
| 0.035 | 0.146 | 0.134 | Protein kinase C alpha inhibitor | 0.134 0.013 DBMET03729 0.079 0.035 DBMET03726 | DBMET03729 | |
| 0.091 | 0.204 | 0.209 | Hemostatic | 0.209 0.029 DBMET03729 0.183 0.04 DBMET03726 | DBMET03729 | |
| 0.016 | 0.129 | 0.049 | Guanylate cyclase inhibitor | 0.049 0.022 DBMET03729 0.044 0.027 DBMET03726 | DBMET03729 | |
| 0.005 | 0.119 | 0.029 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.029 0.019 DBMET03729 0.027 0.02 DBMET03726 | DBMET03729 | |
| 0.024 | 0.141 | 0.083 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.083 0.019 DBMET03729 0.062 0.03 DBMET03726 | DBMET03729 | |
| 0.056 | 0.174 | 0.096 | Lanosterol 14 alpha demethylase inhibitor | 0.096 0.062 DBMET03729 | DBMET03729 | |
| 0.042 | 0.161 | 0.078 | Interferon agonist | 0.078 0.055 DBMET03726 | DBMET03726 | |
| 0.023 | 0.143 | 0.092 | mTOR inhibitor | 0.092 0.014 DBMET03729 0.072 0.021 DBMET03726 | DBMET03729 | |
| 0.022 | 0.144 | 0.08 | Alcohol oxidase inhibitor | 0.063 0.033 DBMET03729 0.08 0.024 DBMET03726 | DBMET03726 | |
| 0.04 | 0.165 | 0.059 | Ryanodine receptor antagonist | 0.057 0.047 DBMET03729 0.059 0.041 DBMET03726 | DBMET03726 | |
| 0.064 | 0.191 | 0.191 | Sodium channel blocker | 0.191 0.036 DBMET03729 0.106 0.104 DBMET03726 | DBMET03729 | |
| 0.032 | 0.159 | 0.056 | 5 Hydroxytryptamine 5 antagonist | 0.056 0.043 DBMET03729 | DBMET03729 | |
| 0.052 | 0.18 | 0.166 | Glycogen synthase kinase-3 alpha inhibitor | 0.166 0.056 DBMET03729 0.127 0.08 DBMET03726 | DBMET03729 | |
| 0.063 | 0.191 | 0.193 | Sodium channel (voltage-gated) blocker | 0.193 0.032 DBMET03729 0.107 0.101 DBMET03726 | DBMET03729 | |
| 0.018 | 0.146 | 0.054 | Glutamate (mGluR1) antagonist | 0.054 0.044 DBMET03729 | DBMET03729 | |
| 0.12 | 0.251 | 0.47 | 5 Hydroxytryptamine release stimulant | 0.47 0.032 DBMET03729 0.419 0.042 DBMET03726 | DBMET03729 | |
| 0.023 | 0.155 | 0.057 | Alpha-mannosidase inhibitor | 0.049 0.045 DBMET03729 0.057 0.032 DBMET03726 | DBMET03726 | |
| 0.015 | 0.148 | 0.095 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.095 0.018 DBMET03729 0.064 0.028 DBMET03726 | DBMET03729 | |
| 0.018 | 0.152 | 0.116 | 5 Hydroxytryptamine 2 agonist | 0.116 0.007 DBMET03729 0.07 0.019 DBMET03726 | DBMET03729 | |
| 0.039 | 0.173 | 0.058 | Phosphodiesterase 1C inhibitor | 0.058 0.054 DBMET03729 | DBMET03729 | |
| 0.102 | 0.237 | 0.142 | ATPase inhibitor | 0.142 0.116 DBMET03729 | DBMET03729 | |
| 0.018 | 0.153 | 0.065 | Adenosine A2a receptor antagonist | 0.058 0.046 DBMET03729 0.065 0.04 DBMET03726 | DBMET03726 | |
| 0.104 | 0.241 | 0.136 | CC chemokine 6 receptor antagonist | 0.136 0.05 DBMET03723 0.121 0.112 DBMET03727 0.135 0.053 DBMET03724 | DBMET03723 | |
| 0.095 | 0.232 | 0.296 | Platelet antagonist | 0.296 0.054 DBMET03723 0.27 0.064 DBMET03724 | DBMET03723 | |
| 0.009 | 0.146 | 0.037 | Methionyl aminopeptidase 1 inhibitor | 0.037 0.015 DBMET03729 | DBMET03729 | |
| 0.178 | 0.317 | 0.388 | MAP kinase kinase 6 inhibitor | 0.388 0.066 DBMET03729 | DBMET03729 | |
| 0.034 | 0.173 | 0.127 | Protein kinase B alpha inhibitor | 0.126 0.016 DBMET03729 0.127 0.016 DBMET03726 | DBMET03726 | |
| 0.024 | 0.165 | 0.137 | CDC7 inhibitor | 0.137 0.012 DBMET03729 0.089 0.03 DBMET03726 | DBMET03729 | |
| 0.163 | 0.304 | 0.233 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.233 0.091 DBMET03729 | DBMET03729 | |
| 0.111 | 0.254 | 0.24 | 5 Hydroxytryptamine 1E antagonist | 0.24 0.085 DBMET03729 0.2 0.131 DBMET03726 | DBMET03729 | |
| 0.099 | 0.244 | 0.158 | Succinate dehydrogenase inhibitor | 0.158 0.098 DBMET03726 | DBMET03726 | |
| 0.02 | 0.167 | 0.086 | Protein kinase C theta inhibitor | 0.086 0.012 DBMET03729 0.062 0.033 DBMET03726 | DBMET03729 | |
| 0.057 | 0.204 | 0.116 | Lipid peroxidase inhibitor | 0.115 0.1 DBMET03725 0.116 0.098 DBMET03726 | DBMET03726 | |
| 0.023 | 0.171 | 0.091 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.091 0.017 DBMET03729 0.078 0.021 DBMET03726 | DBMET03729 | |
| 0.016 | 0.164 | 0.06 | Histamine H2 receptor agonist | 0.06 0.014 DBMET03729 | DBMET03729 | |
| 0.052 | 0.2 | 0.168 | GABA C receptor rho-1 antagonist | 0.168 0.015 DBMET03729 0.154 0.02 DBMET03726 | DBMET03729 | |
| 0.016 | 0.165 | 0.054 | Mannosidase inhibitor | 0.046 0.03 DBMET03729 0.054 0.022 DBMET03726 | DBMET03726 | |
| 0.021 | 0.171 | 0.071 | Nicotinic receptor alpha7 subunit antagonist | 0.071 0.021 DBMET03729 0.056 0.034 DBMET03726 | DBMET03729 | |
| 0.065 | 0.216 | 0.129 | Interleukin 1 antagonist | 0.129 0.076 DBMET03729 | DBMET03729 | |
| 0.009 | 0.16 | 0.031 | Phosphoglycerate kinase inhibitor | 0.031 0.029 DBMET03726 | DBMET03726 | |
| 0.018 | 0.172 | 0.058 | Adenosine A2 receptor antagonist | 0.058 0.051 DBMET03729 0.058 0.051 DBMET03726 | DBMET03726 | |
| 0.057 | 0.211 | 0.333 | Tyrosine kinase inhibitor | 0.333 0.037 DBMET03729 | DBMET03729 | |
| 0.08 | 0.235 | 0.143 | DNA repair enzyme inhibitor | 0.14 0.042 DBMET03729 0.143 0.038 DBMET03726 | DBMET03726 | |
| 0.013 | 0.168 | 0.031 | Protein kinase C beta II inhibitor | 0.031 0.026 DBMET03729 | DBMET03729 | |
| 0.019 | 0.175 | 0.1 | 5 Hydroxytryptamine 2B agonist | 0.1 0.004 DBMET03729 0.062 0.008 DBMET03726 | DBMET03729 | |
| 0.129 | 0.286 | 0.208 | Antithrombotic | 0.202 0.175 DBMET03729 0.208 0.168 DBMET03726 | DBMET03726 | |
| 0.067 | 0.224 | 0.175 | Interleukin 8 antagonist | 0.175 0.021 DBMET03729 0.161 0.028 DBMET03726 | DBMET03729 | |
| 0.09 | 0.248 | 0.172 | MAP kinase 3 inhibitor | 0.172 0.041 DBMET03729 0.124 0.123 DBMET03726 | DBMET03729 | |
| 0.018 | 0.176 | 0.094 | CDK4/cyclin D inhibitor | 0.094 0.016 DBMET03729 0.065 0.032 DBMET03726 | DBMET03729 | |
| 0.079 | 0.238 | 0.121 | NOS3 expression enhancer | 0.121 0.114 DBMET03725 | DBMET03725 | |
| 0.023 | 0.182 | 0.097 | Phosphatidylinositol kinase inhibitor | 0.097 0.022 DBMET03729 0.056 0.045 DBMET03726 | DBMET03729 | |
| 0.04 | 0.2 | 0.212 | Glycogen synthase kinase-3 beta inhibitor | 0.212 0.026 DBMET03729 0.103 0.074 DBMET03726 | DBMET03729 | |
| 0.024 | 0.185 | 0.142 | Cyclin-dependent kinase 4 inhibitor | 0.142 0.013 DBMET03729 0.099 0.027 DBMET03726 | DBMET03729 | |
| 0.02 | 0.182 | 0.138 | Cyclin A2 inhibitor | 0.138 0.015 DBMET03729 0.066 0.042 DBMET03726 | DBMET03729 | |
| 0.06 | 0.222 | 0.131 | Nav1.5 sodium channel blocker | 0.131 0.042 DBMET03729 | DBMET03729 | |
| 0.034 | 0.196 | 0.146 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.146 0.024 DBMET03729 0.131 0.029 DBMET03726 | DBMET03729 | |
| 0.008 | 0.171 | 0.055 | Potassium channel small-conductance Ca-activated activator | 0.055 0.01 DBMET03729 | DBMET03729 | |
| 0.024 | 0.188 | 0.087 | Cyclin D1 inhibitor | 0.087 0.013 DBMET03729 0.07 0.028 DBMET03726 | DBMET03729 | |
| 0.039 | 0.202 | 0.071 | Histone deacetylase SIRT3 inhibitor | 0.071 0.027 DBMET03729 0.063 0.04 DBMET03726 | DBMET03729 | |
| 0.165 | 0.332 | 0.337 | Cyclophilin D inhibitor | 0.337 0.132 DBMET03727 | DBMET03727 | |
| 0.004 | 0.172 | 0.055 | Nicotinic alpha4 receptor agonist | 0.055 0.004 DBMET03729 0.03 0.004 DBMET03726 | DBMET03729 | |
| 0.097 | 0.266 | 0.182 | Phospholipase C inhibitor | 0.164 0.082 DBMET03729 0.182 0.058 DBMET03726 | DBMET03726 | |
| 0.01 | 0.179 | 0.026 | Acid ceramidase inhibitor | 0.026 0.016 DBMET03729 | DBMET03729 | |
| 0.076 | 0.245 | 0.127 | Neuropeptide Y1 antagonist | 0.127 0.106 DBMET03729 | DBMET03729 | |
| 0.169 | 0.338 | 0.364 | Calcium channel L-type activator | 0.364 0.107 DBMET03727 | DBMET03727 | |
| 0.013 | 0.183 | 0.034 | Estrogen-related receptor gamma antagonist | 0.028 0.021 DBMET03729 0.034 0.01 DBMET03726 | DBMET03726 | |
| 0.103 | 0.273 | 0.16 | Neurotensin receptor agonist | 0.154 0.091 DBMET03729 0.16 0.079 DBMET03726 | DBMET03726 | |
| 0.018 | 0.189 | 0.107 | 5 Hydroxytryptamine 6 antagonist | 0.107 0.013 DBMET03729 | DBMET03729 | |
| 0.033 | 0.204 | 0.098 | Focal adhesion kinase 1 inhibitor | 0.098 0.031 DBMET03729 | DBMET03729 | |
| 0.013 | 0.185 | 0.054 | Stearoyl-CoA desaturase inhibitor | 0.054 0.02 DBMET03729 | DBMET03729 | |
| 0.043 | 0.215 | 0.132 | UDP-glucose 4-epimerase inhibitor | 0.107 0.053 DBMET03729 0.132 0.036 DBMET03726 | DBMET03726 | |
| 0.024 | 0.197 | 0.07 | Alpha 1L adrenoreceptor agonist | 0.07 0.005 DBMET03729 0.055 0.012 DBMET03726 | DBMET03729 | |
| 0.026 | 0.199 | 0.046 | Bombesin 2 receptor antagonist | 0.046 0.039 DBMET03726 | DBMET03726 | |
| 0.081 | 0.254 | 0.258 | Aldehyde oxidase inhibitor | 0.164 0.127 DBMET03729 0.258 0.079 DBMET03726 | DBMET03726 | |
| 0.048 | 0.221 | 0.112 | NADH dehydrogenase inhibitor | 0.098 0.046 DBMET03729 0.112 0.033 DBMET03726 | DBMET03726 | |
| 0.039 | 0.216 | 0.208 | Glycogen synthase kinase-3 inhibitor | 0.208 0.03 DBMET03729 | DBMET03729 | |
| 0.034 | 0.211 | 0.074 | Glutamate dehydrogenase inhibitor | 0.074 0.051 DBMET03726 | DBMET03726 | |
| 0.056 | 0.234 | 0.105 | Alpha 2d adrenoreceptor antagonist | 0.105 0.04 DBMET03729 0.087 0.08 DBMET03726 | DBMET03729 | |
| 0.047 | 0.226 | 0.124 | MAP kinase 13 inhibitor | 0.124 0.053 DBMET03729 | DBMET03729 | |
| 0.008 | 0.187 | 0.097 | Diamine oxidase inhibitor | 0.097 0.004 DBMET03729 0.075 0.005 DBMET03726 | DBMET03729 | |
| 0.062 | 0.242 | 0.367 | Peroxidase inhibitor | 0.31 0.035 DBMET03729 0.367 0.025 DBMET03726 | DBMET03726 | |
| 0.01 | 0.191 | 0.037 | CDK4/cyclin D3 inhibitor | 0.037 0.012 DBMET03729 0.031 0.016 DBMET03726 | DBMET03729 | |
| 0.064 | 0.245 | 0.157 | Protein kinase stimulant | 0.157 0.064 DBMET03726 | DBMET03726 | |
| 0.036 | 0.217 | 0.161 | Pim-3 kinase inhibitor | 0.161 0.015 DBMET03729 0.121 0.031 DBMET03726 | DBMET03729 | |
| 0.077 | 0.259 | 0.117 | Insulin secretagoues | 0.117 0.115 DBMET03726 | DBMET03726 | |
| 0.024 | 0.206 | 0.071 | Na+ K+ transporting ATPase inhibitor | 0.071 0.059 DBMET03726 | DBMET03726 | |
| 0.025 | 0.207 | 0.104 | Leucine-rich repeat kinase 2 inhibitor | 0.104 0.04 DBMET03729 | DBMET03729 | |
| 0.046 | 0.228 | 0.179 | GABA C receptor antagonist | 0.17 0.021 DBMET03729 0.179 0.018 DBMET03726 | DBMET03726 | |
| 0.026 | 0.208 | 0.116 | Nav1.7 sodium channel blocker | 0.116 0.018 DBMET03729 | DBMET03729 | |
| 0.076 | 0.258 | 0.167 | Hepatoprotectant | 0.167 0.092 DBMET03723 0.161 0.098 DBMET03727 0.164 0.095 DBMET03724 | DBMET03723 | |
| 0.069 | 0.254 | 0.183 | Aurora-C kinase inhibitor | 0.183 0.025 DBMET03729 0.145 0.057 DBMET03726 | DBMET03729 | |
| 0.017 | 0.202 | 0.105 | CDK4/cyclin D1 inhibitor | 0.105 0.013 DBMET03729 0.082 0.023 DBMET03726 | DBMET03729 | |
| 0.022 | 0.208 | 0.07 | Syk tyrosine kinase inhibitor | 0.07 0.049 DBMET03729 0.062 0.057 DBMET03726 | DBMET03729 | |
| 0.057 | 0.244 | 0.111 | Adenylate kinase inhibitor | 0.103 0.062 DBMET03729 0.111 0.052 DBMET03726 | DBMET03726 | |
| 0.008 | 0.196 | 0.03 | Myristoyl transferase inhibitor | 0.03 0.013 DBMET03729 | DBMET03729 | |
| 0.017 | 0.205 | 0.122 | Cyclin A inhibitor | 0.122 0.017 DBMET03729 0.057 0.046 DBMET03726 | DBMET03729 | |
| 0.017 | 0.205 | 0.081 | Protein kinase C epsilon inhibitor | 0.081 0.019 DBMET03729 | DBMET03729 | |
| 0.007 | 0.196 | 0.25 | 5 Hydroxytryptamine 2C agonist | 0.25 0.004 DBMET03729 0.15 0.005 DBMET03726 | DBMET03729 | |
| 0.006 | 0.196 | 0.052 | Nicotinic alpha3beta4 receptor agonist | 0.052 0.005 DBMET03729 0.041 0.009 DBMET03726 | DBMET03729 | |
| 0.125 | 0.315 | 0.218 | Insulysin inhibitor | 0.218 0.132 DBMET03729 0.216 0.135 DBMET03726 | DBMET03729 | |
| 0.097 | 0.287 | 0.191 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.191 0.082 DBMET03729 0.183 0.091 DBMET03726 | DBMET03729 | |
| 0.011 | 0.203 | 0.067 | Dopamine D5 agonist | 0.046 0.021 DBMET03729 0.067 0.009 DBMET03726 | DBMET03726 | |
| 0.03 | 0.222 | 0.284 | Protein kinase (CK1) delta inhibitor | 0.284 0.013 DBMET03729 0.179 0.037 DBMET03726 | DBMET03729 | |
| 0.026 | 0.218 | 0.077 | DNA gyrase inhibitor | 0.077 0.029 DBMET03729 0.061 0.047 DBMET03726 | DBMET03729 | |
| 0.036 | 0.228 | 0.166 | Hepatocyte growth factor antagonist | 0.113 0.04 DBMET03729 0.166 0.018 DBMET03726 | DBMET03726 | |
| 0.083 | 0.276 | 0.177 | CF transmembrane conductance regulator agonist | 0.147 0.082 DBMET03729 0.177 0.039 DBMET03726 | DBMET03726 | |
| 0.022 | 0.216 | 0.161 | CDK2/cyclin E2 inhibitor | 0.161 0.015 DBMET03729 0.108 0.026 DBMET03726 | DBMET03729 | |
| 0.079 | 0.274 | 0.23 | Platelet aggregation inhibitor | 0.23 0.062 DBMET03723 0.181 0.097 DBMET03724 | DBMET03723 | |
| 0.02 | 0.215 | 0.05 | Aconitate hydratase inhibitor | 0.05 0.039 DBMET03729 | DBMET03729 | |
| 0.016 | 0.213 | 0.058 | Protein kinase (CK2) beta inhibitor | 0.058 0.005 DBMET03729 0.053 0.006 DBMET03726 | DBMET03729 | |
| 0.146 | 0.346 | 0.19 | MAP kinase kinase 3 inhibitor | 0.19 0.153 DBMET03729 | DBMET03729 | |
| 0.019 | 0.219 | 0.088 | Vanilloid antagonist | 0.088 0.042 DBMET03729 | DBMET03729 | |
| 0.033 | 0.236 | 0.077 | AXL receptor tyrosine kinase inhibitor | 0.077 0.065 DBMET03729 | DBMET03729 | |
| 0.035 | 0.239 | 0.068 | Exportin-1 inhibitor | 0.068 0.048 DBMET03729 | DBMET03729 | |
| 0.07 | 0.277 | 0.141 | Nitric oxide antagonist | 0.141 0.104 DBMET03727 | DBMET03727 | |
| 0.021 | 0.229 | 0.085 | Carbonic anhydrase stimulant | 0.085 0.024 DBMET03729 0.069 0.032 DBMET03726 | DBMET03729 | |
| 0.024 | 0.232 | 0.073 | Cyclin H inhibitor | 0.073 0.025 DBMET03729 0.054 0.047 DBMET03726 | DBMET03729 | |
| 0.023 | 0.236 | 0.117 | Aurora-A kinase inhibitor | 0.117 0.056 DBMET03729 | DBMET03729 | |
| 0.039 | 0.253 | 0.678 | Chelator | 0.519 0.004 DBMET03725 0.393 0.006 DBMET03724 0.678 0.003 DBMET03726 | DBMET03726 | |
| 0.005 | 0.221 | 0.05 | Nicotinic alpha4beta2 receptor agonist | 0.05 0.004 DBMET03729 0.042 0.007 DBMET03726 | DBMET03729 | |
| 0.046 | 0.262 | 0.211 | Alpha-N-acetylglucosaminidase inhibitor | 0.192 0.037 DBMET03729 0.211 0.031 DBMET03726 | DBMET03726 | |
| 0.07 | 0.288 | 0.216 | Polo-like kinase-3 inhibitor | 0.216 0.037 DBMET03729 0.192 0.05 DBMET03726 | DBMET03729 | |
| 0.079 | 0.299 | 0.266 | Vasodilator | 0.266 0.061 DBMET03723 0.242 0.073 DBMET03724 | DBMET03723 | |
| 0.108 | 0.331 | 0.212 | RNA-directed DNA polymerase inhibitor | 0.206 0.091 DBMET03729 0.212 0.083 DBMET03726 | DBMET03726 | |
| 0.048 | 0.274 | 0.077 | MAP kinase 7 inhibitor | 0.077 0.057 DBMET03729 | DBMET03729 | |
| 0.024 | 0.249 | 0.067 | Aminopeptidase I inhibitor | 0.067 0.058 DBMET03729 | DBMET03729 | |
| 0.063 | 0.289 | 0.141 | Transcription factor STAT6 inhibitor | 0.141 0.03 DBMET03729 0.128 0.046 DBMET03726 | DBMET03729 | |
| 0.073 | 0.301 | 0.323 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.323 0.036 DBMET03729 0.26 0.054 DBMET03726 | DBMET03729 | |
| 0.123 | 0.352 | 0.266 | Tyrosine 3 hydroxylase inhibitor | 0.234 0.085 DBMET03729 0.266 0.054 DBMET03726 | DBMET03726 | |
| 0.022 | 0.251 | 0.09 | Protein kinase C iota inhibitor | 0.09 0.022 DBMET03729 | DBMET03729 | |
| 0.018 | 0.25 | 0.057 | Myc inhibitor | 0.057 0.034 DBMET03729 | DBMET03729 | |
| 0.04 | 0.275 | 0.167 | Ribosomal protein S6 kinase inhibitor | 0.167 0.054 DBMET03729 0.151 0.064 DBMET03726 | DBMET03729 | |
| 0.015 | 0.252 | 0.073 | Pim-2 kinase inhibitor | 0.073 0.023 DBMET03729 0.055 0.038 DBMET03726 | DBMET03729 | |
| 0.022 | 0.263 | 0.12 | Protein kinase (CK2) inhibitor | 0.12 0.048 DBMET03729 0.12 0.048 DBMET03726 | DBMET03726 | |
| 0.039 | 0.282 | 0.124 | MAP kinase 12 inhibitor | 0.124 0.066 DBMET03729 | DBMET03729 | |
| 0.024 | 0.266 | 0.112 | Protein kinase (CK2) alpha inhibitor | 0.112 0.067 DBMET03729 0.104 0.073 DBMET03726 | DBMET03729 | |
| 0.013 | 0.258 | 0.059 | Argininosuccinate synthase inhibitor | 0.049 0.048 DBMET03729 0.059 0.038 DBMET03726 | DBMET03726 | |
| 0.016 | 0.263 | 0.044 | Transforming growth factor beta 1 antagonist | 0.044 0.041 DBMET03729 | DBMET03729 | |
| 0.02 | 0.269 | 0.228 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.228 0.03 DBMET03729 0.101 0.079 DBMET03726 | DBMET03729 | |
| 0.019 | 0.269 | 0.065 | Glutamate decarboxylase inhibitor | 0.065 0.061 DBMET03726 | DBMET03726 | |
| 0.028 | 0.28 | 0.313 | Protein kinase (CK1) inhibitor | 0.313 0.016 DBMET03729 0.18 0.048 DBMET03726 | DBMET03729 | |
| 0.014 | 0.268 | 0.084 | Fibroblast growth factor 3 antagonist | 0.084 0.045 DBMET03729 | DBMET03729 | |
| 0.018 | 0.272 | 0.102 | Histidine decarboxylase inhibitor | 0.062 0.059 DBMET03729 0.102 0.031 DBMET03726 | DBMET03726 | |
| 0.013 | 0.271 | 0.071 | Phosphofructokinase-1 inhibitor | 0.071 0.047 DBMET03726 | DBMET03726 | |
| 0.026 | 0.284 | 0.082 | Alpha 1b adrenoreceptor agonist | 0.082 0.008 DBMET03729 0.069 0.013 DBMET03726 | DBMET03729 | |
| 0.031 | 0.292 | 0.179 | Protein kinase C mu inhibitor | 0.09 0.067 DBMET03728 0.179 0.016 DBMET03729 0.135 0.033 DBMET03726 | DBMET03729 | |
| 0.015 | 0.276 | 0.047 | CDK7/cyclin H inhibitor | 0.047 0.029 DBMET03729 | DBMET03729 | |
| 0.046 | 0.307 | 0.143 | Cytokine production inhibitor | 0.143 0.068 DBMET03729 | DBMET03729 | |
| 0.008 | 0.27 | 0.078 | Alpha 1d adrenoreceptor agonist | 0.078 0.005 DBMET03729 0.058 0.012 DBMET03726 | DBMET03729 | |
| 0.013 | 0.279 | 0.075 | Cyclin A1 inhibitor | 0.075 0.017 DBMET03729 0.057 0.044 DBMET03726 | DBMET03729 | |
| 0.017 | 0.284 | 0.116 | Phenylalanine 4-hydroxylase inhibitor | 0.099 0.026 DBMET03729 0.116 0.019 DBMET03726 | DBMET03726 | |
| 0.007 | 0.275 | 0.036 | 5 Hydroxytryptamine 6 agonist | 0.036 0.01 DBMET03729 | DBMET03729 | |
| 0.056 | 0.325 | 0.138 | Thiol protease inhibitor | 0.138 0.082 DBMET03729 | DBMET03729 | |
| 0.11 | 0.381 | 0.266 | Nitric-oxide synthase stimulant | 0.251 0.032 DBMET03729 0.266 0.023 DBMET03726 | DBMET03726 | |
| 0.099 | 0.37 | 0.412 | Antiobesity | 0.412 0.061 DBMET03729 0.272 0.138 DBMET03726 | DBMET03729 | |
| 0.035 | 0.306 | 0.133 | Tyrosine-protein kinase receptor antagonist | 0.133 0.075 DBMET03729 | DBMET03729 | |
| 0.018 | 0.29 | 0.068 | Lysine-specific demethylase 1A inhibitor | 0.068 0.019 DBMET03729 0.058 0.031 DBMET03726 | DBMET03729 | |
| 0.025 | 0.297 | 0.174 | RET inhibitor | 0.174 0.05 DBMET03729 | DBMET03729 | |
| 0.005 | 0.277 | 0.029 | Cyclin E2 inhibitor | 0.029 0.02 DBMET03729 | DBMET03729 | |
| 0.09 | 0.364 | 0.182 | Cholesterol antagonist | 0.182 0.181 DBMET03726 | DBMET03726 | |
| 0.038 | 0.313 | 0.108 | MAP kinase kinase 7 inhibitor | 0.098 0.015 DBMET03729 0.108 0.008 DBMET03726 | DBMET03726 | |
| 0.054 | 0.329 | 0.251 | MAP kinase kinase 2 inhibitor | 0.251 0.053 DBMET03729 0.222 0.068 DBMET03726 | DBMET03729 | |
| 0.033 | 0.311 | 0.169 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.169 0.056 DBMET03729 0.135 0.074 DBMET03726 | DBMET03729 | |
| 0.014 | 0.298 | 0.066 | Beta 1 adrenoreceptor antagonist | 0.05 0.047 DBMET03729 0.066 0.03 DBMET03726 | DBMET03726 | |
| 0.021 | 0.305 | 0.086 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.086 0.028 DBMET03729 | DBMET03729 | |
| 0.009 | 0.294 | 0.059 | CDK1/cyclin B inhibitor | 0.059 0.048 DBMET03729 | DBMET03729 | |
| 0.025 | 0.312 | 0.113 | Aurora-B kinase inhibitor | 0.113 0.07 DBMET03729 | DBMET03729 | |
| 0.075 | 0.362 | 0.123 | Sphingosine 1-phosphate receptor 5 antagonist | 0.123 0.118 DBMET03726 | DBMET03726 | |
| 0.007 | 0.297 | 0.067 | Cyclin E1 inhibitor | 0.067 0.029 DBMET03729 | DBMET03729 | |
| 0.048 | 0.337 | 0.157 | Protein kinase (CK1) gamma 3 inhibitor | 0.157 0.082 DBMET03729 0.146 0.094 DBMET03726 | DBMET03729 | |
| 0.035 | 0.326 | 0.1 | Protein kinase (CK1) gamma 2 inhibitor | 0.1 0.084 DBMET03729 0.096 0.089 DBMET03726 | DBMET03729 | |
| 0.004 | 0.296 | 0.024 | Methionyl aminopeptidase 2 inhibitor | 0.024 0.019 DBMET03729 | DBMET03729 | |
| 0.059 | 0.352 | 0.125 | Interleukin 2 antagonist | 0.125 0.038 DBMET03729 | DBMET03729 | |
| 0.015 | 0.311 | 0.055 | Beta 2 adrenoreceptor antagonist | 0.055 0.029 DBMET03726 | DBMET03726 | |
| 0.023 | 0.32 | 0.081 | Glycine receptor antagonist | 0.08 0.057 DBMET03729 0.081 0.056 DBMET03726 | DBMET03726 | |
| 0.014 | 0.311 | 0.036 | ATR kinase inhibitor | 0.036 0.017 DBMET03729 | DBMET03729 | |
| 0.045 | 0.345 | 0.608 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.215 0.06 DBMET03725 0.229 0.055 DBMET03729 0.131 0.113 DBMET03724 0.608 0.005 DBMET03726 | DBMET03726 | |
| 0.033 | 0.336 | 0.122 | DNA directed RNA polymerase inhibitor | 0.122 0.036 DBMET03723 0.116 0.04 DBMET03724 | DBMET03723 | |
| 0.051 | 0.354 | 0.292 | Death-associated protein kinase 3 inhibitor | 0.292 0.04 DBMET03729 0.24 0.056 DBMET03726 | DBMET03729 | |
| 0.003 | 0.306 | 0.017 | Cyclin T1 inhibitor | 0.017 0.014 DBMET03729 | DBMET03729 | |
| 0.12 | 0.427 | 0.282 | 5 Hydroxytryptamine uptake stimulant | 0.282 0.055 DBMET03729 0.271 0.063 DBMET03726 | DBMET03729 | |
| 0.029 | 0.337 | 0.115 | TRKA antagonist | 0.115 0.072 DBMET03729 | DBMET03729 | |
| 0.038 | 0.348 | 0.089 | Granulocyte macrophage colony stimulating factor agonist | 0.089 0.054 DBMET03729 0.083 0.066 DBMET03726 | DBMET03729 | |
| 0.004 | 0.315 | 0.016 | CDK2/cyclin A3 inhibitor | 0.016 0.012 DBMET03729 | DBMET03729 | |
| 0.041 | 0.353 | 0.121 | Hedgehog signaling inhibitor | 0.121 0.039 DBMET03729 | DBMET03729 | |
| 0.005 | 0.318 | 0.037 | 1,3-Beta-glucan synthase inhibitor | 0.037 0.005 DBMET03728 | DBMET03728 | |
| 0.019 | 0.334 | 0.111 | CDK2/cyclin A inhibitor | 0.111 0.049 DBMET03729 | DBMET03729 | |
| 0.02 | 0.336 | 0.136 | CDK/cyclin complex inhibitor | 0.136 0.034 DBMET03729 0.077 0.072 DBMET03726 | DBMET03729 | |
| 0.006 | 0.324 | 0.081 | Cyclin E inhibitor | 0.081 0.032 DBMET03729 | DBMET03729 | |
| 0.032 | 0.355 | 0.198 | Protein kinase C nu inhibitor | 0.198 0.048 DBMET03729 0.155 0.067 DBMET03726 | DBMET03729 | |
| 0.025 | 0.348 | 0.12 | TRKB antagonist | 0.12 0.072 DBMET03729 | DBMET03729 | |
| 0.029 | 0.352 | 0.194 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.186 0.056 DBMET03729 0.194 0.053 DBMET03726 | DBMET03726 | |
| 0.018 | 0.344 | 0.097 | Fibroblast growth factor 1 antagonist | 0.097 0.06 DBMET03729 | DBMET03729 | |
| 0.023 | 0.348 | 0.11 | Lck kinase inhibitor | 0.11 0.093 DBMET03729 | DBMET03729 | |
| 0.039 | 0.368 | 0.105 | DOPA decarboxylase inhibitor | 0.105 0.066 DBMET03726 | DBMET03726 | |
| 0.031 | 0.361 | 0.129 | Src kinase inhibitor | 0.129 0.1 DBMET03729 | DBMET03729 | |
| 0.03 | 0.362 | 0.167 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.143 0.094 DBMET03729 0.167 0.079 DBMET03726 | DBMET03726 | |
| 0.006 | 0.339 | 0.056 | Nicotinic acid receptor 2 agonist | 0.032 0.03 DBMET03725 0.056 0.012 DBMET03726 | DBMET03726 | |
| 0.03 | 0.365 | 0.143 | Estrogen receptor beta antagonist | 0.113 0.042 DBMET03725 0.102 0.06 DBMET03724 0.143 0.017 DBMET03726 | DBMET03726 | |
| 0.038 | 0.374 | 0.14 | Estrogen antagonist | 0.12 0.055 DBMET03725 0.111 0.073 DBMET03724 0.14 0.028 DBMET03726 | DBMET03726 | |
| 0.023 | 0.359 | 0.079 | Myeloperoxidase inhibitor | 0.079 0.069 DBMET03729 | DBMET03729 | |
| 0.033 | 0.371 | 0.08 | Bromodomain-containing protein 2 inhibitor | 0.08 0.077 DBMET03729 | DBMET03729 | |
| 0.002 | 0.343 | 0.013 | Imidazoline I2 receptor antagonist | 0.013 0.006 DBMET03729 | DBMET03729 | |
| 0.005 | 0.348 | 0.053 | CDK2/cyclin E inhibitor | 0.053 0.05 DBMET03729 | DBMET03729 | |
| 0.03 | 0.374 | 0.113 | Growth factor antagonist | 0.113 0.099 DBMET03729 0.11 0.103 DBMET03726 | DBMET03729 | |
| 0.015 | 0.363 | 0.08 | CDK1/cyclin B1 inhibitor | 0.08 0.039 DBMET03729 0.075 0.042 DBMET03726 | DBMET03729 | |
| 0.015 | 0.365 | 0.097 | CYP2A6 inhibitor | 0.097 0.037 DBMET03729 | DBMET03729 | |
| 0.021 | 0.372 | 0.152 | Cyclin-dependent kinase 9 inhibitor | 0.152 0.033 DBMET03729 0.127 0.042 DBMET03726 | DBMET03729 | |
| 0.004 | 0.356 | 0.036 | Imidazoline I1 receptor antagonist | 0.036 0.005 DBMET03729 | DBMET03729 | |
| 0.048 | 0.405 | 0.182 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.178 0.096 DBMET03729 0.182 0.092 DBMET03726 | DBMET03726 | |
| 0.068 | 0.425 | 0.171 | Hypoglycemic | 0.171 0.146 DBMET03727 | DBMET03727 | |
| 0.015 | 0.374 | 0.059 | Epithelial sodium channel blocker | 0.059 0.03 DBMET03729 0.052 0.043 DBMET03726 | DBMET03729 | |
| 0.017 | 0.377 | 0.146 | Cyclin-dependent kinase 2 inhibitor | 0.146 0.04 DBMET03729 0.088 0.085 DBMET03726 | DBMET03729 | |
| 0.022 | 0.382 | 0.15 | MAP-kinase-activated kinase inhibitor | 0.15 0.015 DBMET03729 0.099 0.04 DBMET03726 | DBMET03729 | |
| 0.054 | 0.415 | 0.137 | 3C-like protease (Human coronavirus) inhibitor | 0.137 0.125 DBMET03729 | DBMET03729 | |
| 0.07 | 0.434 | 0.153 | MAP kinase kinase 4 inhibitor | 0.15 0.061 DBMET03729 0.153 0.055 DBMET03726 | DBMET03726 | |
| 0.012 | 0.377 | 0.112 | Rho-associated kinase I inhibitor | 0.112 0.024 DBMET03729 0.068 0.059 DBMET03726 | DBMET03729 | |
| 0.026 | 0.394 | 0.104 | MAP kinase kinase 1 inhibitor | 0.104 0.052 DBMET03729 | DBMET03729 | |
| 0.032 | 0.402 | 0.226 | I kappa B kinase epsilon inhibitor | 0.226 0.051 DBMET03729 0.206 0.066 DBMET03726 | DBMET03729 | |
| 0.016 | 0.39 | 0.132 | MAP-kinase-activated kinase 2 inhibitor | 0.132 0.016 DBMET03729 0.082 0.042 DBMET03726 | DBMET03729 | |
| 0.069 | 0.446 | 0.125 | Death-associated protein kinase 1 inhibitor | 0.125 0.097 DBMET03729 | DBMET03729 | |
| 0.026 | 0.409 | 0.077 | GABA B receptor agonist | 0.077 0.049 DBMET03726 | DBMET03726 | |
| 0.032 | 0.416 | 0.123 | Toll-Like receptor 2 antagonist | 0.123 0.075 DBMET03726 | DBMET03726 | |
| 0.021 | 0.405 | 0.213 | Cyclin-dependent kinase inhibitor | 0.213 0.034 DBMET03729 0.12 0.074 DBMET03726 | DBMET03729 | |
| 0.022 | 0.41 | 0.094 | Gastric antisecretory | 0.094 0.073 DBMET03729 | DBMET03729 | |
| 0.015 | 0.405 | 0.063 | Beta adrenoreceptor antagonist | 0.063 0.049 DBMET03726 | DBMET03726 | |
| 0.004 | 0.394 | 0.024 | Alpha 2b adrenoreceptor agonist | 0.024 0.006 DBMET03729 | DBMET03729 | |
| 0.01 | 0.404 | 0.035 | Estrogen-related receptor beta antagonist | 0.035 0.018 DBMET03726 | DBMET03726 | |
| 0.032 | 0.434 | 0.113 | Cell wall synthesis inhibitor | 0.113 0.11 DBMET03726 | DBMET03726 | |
| 0.024 | 0.436 | 0.107 | Beta glucuronidase inhibitor | 0.092 0.085 DBMET03729 0.107 0.06 DBMET03726 | DBMET03726 | |
| 0.016 | 0.429 | 0.103 | Protein-tyrosine kinase Lyn inhibitor | 0.103 0.1 DBMET03729 | DBMET03729 | |
| 0.017 | 0.43 | 0.114 | MAP kinase kinase inhibitor | 0.114 0.08 DBMET03729 | DBMET03729 | |
| 0.023 | 0.439 | 0.208 | Cyclin-dependent kinase 7 inhibitor | 0.208 0.031 DBMET03729 0.144 0.064 DBMET03726 | DBMET03729 | |
| 0.014 | 0.437 | 0.059 | I kappa B kinase 2 inhibitor | 0.059 0.048 DBMET03729 | DBMET03729 | |
| 0.041 | 0.466 | 0.357 | Antioxidant | 0.266 0.076 DBMET03725 0.263 0.077 DBMET03724 0.357 0.045 DBMET03726 | DBMET03726 | |
| 0.033 | 0.459 | 0.165 | Cyclin-dependent kinase 8 inhibitor | 0.165 0.065 DBMET03729 0.148 0.081 DBMET03726 | DBMET03729 | |
| 0.013 | 0.441 | 0.066 | Protein kinase B gamma inhibitor | 0.066 0.064 DBMET03729 | DBMET03729 | |
| 0.063 | 0.491 | 0.163 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.163 0.12 DBMET03726 | DBMET03726 | |
| 0.023 | 0.453 | 0.218 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.211 0.069 DBMET03729 0.218 0.064 DBMET03726 | DBMET03726 | |
| 0.014 | 0.451 | 0.086 | HIV-1 integrase inhibitor | 0.086 0.034 DBMET03728 | DBMET03728 | |
| 0.016 | 0.454 | 0.046 | Topoisomerase II beta inhibitor | 0.046 0.04 DBMET03726 | DBMET03726 | |
| 0.002 | 0.447 | 0.028 | Alpha 2a adrenoreceptor agonist | 0.028 0.005 DBMET03729 0.019 0.01 DBMET03726 | DBMET03729 | |
| 0.013 | 0.474 | 0.072 | Cyclin B3 inhibitor | 0.072 0.044 DBMET03729 0.067 0.048 DBMET03726 | DBMET03729 | |
| 0.008 | 0.47 | 0.124 | Cyclin-dependent kinase 1 inhibitor | 0.124 0.053 DBMET03729 0.102 0.065 DBMET03726 | DBMET03729 | |
| 0.054 | 0.543 | 0.31 | Toll-Like receptor agonist | 0.31 0.104 DBMET03726 | DBMET03726 | |
| 0.055 | 0.545 | 0.314 | Toll-Like receptor 7 agonist | 0.314 0.102 DBMET03726 | DBMET03726 | |
| 0.005 | 0.497 | 0.022 | Alpha 2d adrenoreceptor agonist | 0.022 0.014 DBMET03729 | DBMET03729 | |
| 0.013 | 0.514 | 0.074 | I kappa B kinase inhibitor | 0.074 0.07 DBMET03729 | DBMET03729 | |
| 0.011 | 0.528 | 0.149 | CDC-like kinase 2 inhibitor | 0.149 0.093 DBMET03729 | DBMET03729 | |
| 0.021 | 0.538 | 0.087 | HIV-1 integrase (Overall Integration) inhibitor | 0.087 0.068 DBMET03726 | DBMET03726 | |
| 0.002 | 0.522 | 0.023 | Alpha 2c adrenoreceptor agonist | 0.023 0.008 DBMET03729 | DBMET03729 | |
| 0.029 | 0.554 | 0.078 | D-Ala-D-Ala ligase inhibitor | 0.078 0.073 DBMET03726 | DBMET03726 | |
| 0.03 | 0.557 | 0.104 | CDK3/cyclin E inhibitor | 0.104 0.079 DBMET03729 0.098 0.091 DBMET03726 | DBMET03729 | |
| 0.007 | 0.541 | 0.12 | Pim-1 kinase inhibitor | 0.12 0.042 DBMET03729 0.084 0.074 DBMET03726 | DBMET03729 | |
| 0.008 | 0.555 | 0.089 | Rho-associated kinase inhibitor | 0.089 0.04 DBMET03729 | DBMET03729 | |
| 0.005 | 0.557 | 0.035 | Alpha 1a adrenoreceptor agonist | 0.035 0.008 DBMET03729 | DBMET03729 | |
| 0.005 | 0.56 | 0.088 | Cyclin-dependent kinase 5 inhibitor | 0.088 0.086 DBMET03729 | DBMET03729 | |
| 0.01 | 0.565 | 0.166 | CDC-like kinase 4 inhibitor | 0.166 0.089 DBMET03729 | DBMET03729 | |
| 0.008 | 0.576 | 0.143 | Clk dual-specificity kinase inhibitor | 0.143 0.12 DBMET03729 | DBMET03729 | |
| 0.012 | 0.579 | 0.117 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.117 0.111 DBMET03729 | DBMET03729 | |
| 0.009 | 0.583 | 0.048 | Purinergic P2X4 antagonist | 0.048 0.028 DBMET03729 0.044 0.036 DBMET03726 | DBMET03729 | |
| 0.059 | 0.649 | 0.399 | Antiinflammatory | 0.399 0.14 DBMET03723 0.332 0.187 DBMET03724 | DBMET03723 | |
| 0.005 | 0.633 | 0.078 | Protein kinase A inhibitor | 0.078 0.062 DBMET03729 0.077 0.063 DBMET03726 | DBMET03729 | |
| 0.005 | 0.635 | 0.061 | Check point kinase 1 inhibitor | 0.061 0.057 DBMET03729 | DBMET03729 | |
| 0.007 | 0.769 | 0.138 | Purinergic P2X2 antagonist | 0.138 0.014 DBMET03726 | DBMET03726 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |